FDA Approves ASCENIV(TM), A Novel Intravenous Immune Globulin (NASDAQ: ADMA)
Channel: RICH TV LIVE
Date: 2019-04-02

FDA Approves ASCENIV(TM), A Novel Intravenous Immune Globulin (NASDAQ: ADMA) - April 2, 2019 - RICH TV LIVE - ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration ("FDA") has approved ASCENIV(TM), Immune Globulin Intravenous, Human - slra 10% Liquid, formerly referred to as RI-002. ASCENIV(TM) is an Intravenous Immune Globulin ("IVIG") drug product for the treatment of Primary Humoral Immunodeficiency Disease ("PIDD" or "PI") in adults and adolescents (12 to 17 years of age). The Company anticipates having the product available for commercial launch during the second half of 2019.

The ASCENIV(TM) pivotal Phase III clinical study followed FDA guidance for treatment of patients with PI. The study enrolled fifty-nine patients with PI at nine sites across the U.S. in which study patients received regular infusions of ASCENIV(TM) over the course of one year. The trial's primary endpoint evaluated the rate of Serious Bacterial Infections ("SBI") in patients treated with ASCENIV(TM). Secondary endpoints included time to first SBI and to first serious infection, days on antibiotics, days off school or work due to infections, all confirmed infections of any kind, and hospitalizations due to infection. There were zero SBIs during the 12-month study period. The manuscript and data set describing the results are published by Dr. Richard Wasserman, et al in the Journal of Clinical Immunology (2016) Volume 36: 590-599. The approved labeling will include a boxed warning about potential thrombosis and renal dysfunction or failure, as well as the most common adverse events observed in the pivotal study, which were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.

Subscribe - https://www.youtube.com/c/RICHTVLIVE
Visit - http://www.richtvlive.com/ a FREE community for stocks, sports, travel, and trending topics. #richtvlive #stocks #education 

24/7 Free Stock Chat https://t.me/joinchat/FR1YMRfXZdpX2bR_D3tJAw

ILL KIDD Productions Playlist - https://www.youtube.com/playlist?

Join the RICH TV LIVE FREE Social Media Community - Download the Amino app on your phone or computer and follow the link - https://aminoapps.com/c/RICHTVLIVE/home/

RICH TV LIVE Clothing - https://teespring.com/stores/rich-tv-live
list=PLiBGEhbXkQPCHTZsUlx-GxSGgsCLUSKJO

Popular Uploads - https://goo.gl/tbvXGg
Most Recent Upload - https://goo.gl/unKXBy
YouTube Channel Page - https://goo.gl/yUdG7w
Subscribe - https://goo.gl/q2tLnn
Rich TV Live Playlist - https://goo.gl/e116JF
RICH TV LIVE TOP 10 STOCKS Playlist - https://www.youtube.com/playlist?list=PLiBGEhbXkQPCfeYmBKHyXXu8dZc3YkkbW&disable_polymer=true

Disclaimer

RICH TV LIVE company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RICH TV LIVE reports company profiles or other investor relations materials and presentations are subject to change. RICH TV LIVE and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

Investing is inherently risky. RICH TV LIVE is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. Disclosure - https://www.richtvlive.com/feature-.html

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov/Canadian CSA https://www.securities-administrators.ca/.